#United States #biopharmaceuticals #Houston #RBL LLC #Chris Duke

RBL LLC Welcomes Chris Duke as Operating Partner

In a significant move aimed at enhancing its leadership, RBL LLC has recently appointed Chris Duke as its new Operating Partner. This innovative biotech venture creation studio, located in Houston, is renowned for its commitment to quickly cultivating companies based on revolutionary medical technologies derived from leading research institutions.

Chris Duke, who has previously held high-profile executive roles in the biopharmaceutical sector, becomes part of RBL's dedicated team that strives to expedite the journey of lifesaving therapies from research to patient delivery. His prior experience as the CEO of Gennao Bio is particularly noteworthy, as he brings a wealth of knowledge in rare diseases and gene therapy to RBL.

RBL's Managing Partner, Paul Wotton, expressed enthusiasm about Duke’s appointment, stating, "Securing a leader of Chris' caliber represents a significant addition to RBL. Few executives possess his unique combination of scientific, operational, and commercial expertise." Wotton emphasized that Duke's insights into venture creation and global business strategy will be crucial as the company builds multiple biotech enterprises simultaneously. This collaborative effort aims to hone in on the most promising medical innovations that can benefit patients in need.

Duke himself has acknowledged the rapid evolution of the biotech ecosystem in Houston, where academic innovation increasingly underpins new company formation. He stated, "RBL has the potential to play a pivotal role in translating academic research into clinical applications that improve how lifesaving therapies are developed and delivered." This forward-thinking ethos aligns perfectly with RBL's mission to drastically shorten the timeline for effective therapies to reach those who need them most.

Prior to joining RBL, Duke had an impactful career at Gennao Bio, where he assumed the role of COO in September 2020 and transitioned to CEO in October 2022. His previous positions include Chief Operating Officer at Advaxis, Inc., and Vice President of Global Commercial Operations at Amicus Therapeutics, where he managed extensive international commercial operations across multiple regions, including Europe, Japan, Latin America, and Canada.

Duke's strategic leadership has been characterized by overseeing global programs from preclinical development through late-stage clinical trials while nurturing key alliances with prominent pharmaceutical partners. Additionally, his tenure as Entrepreneur-in-Residence at Harvard University's Office of Technology Development enriched his experience, allowing him to evaluate innovations and push for new startup opportunities.

Academically, Duke is well-equipped for his role, holding a Master's degree in Business Administration from The Wharton School and a Master's in Public Health from Rutgers University.

About RBL LLC

RBL LLC is a pioneering venture creation studio in the biotech sector, dedicated to the rapid development of groundbreaking medical technologies. The firm provides a robust framework for entrepreneurs, researchers, and innovators, offering essential financial support, strategic guidance, and access to lab facilities within the Texas Medical Center Helix Park. The company's mission revolves around using innovation to accelerate healthcare advancements.

By bolstering its leadership team, RBL aims to harness Duke's extensive background to refine and expand its operations, reinforcing its position as a leader in biotech venture creation. As companies seek to navigate the intersection of scientific innovation and commercial viability, strong leadership like Duke’s will undoubtedly pave the way for significant advancements in the field of medicine.